buy the dip, sell the rip on Moderna. Moderna (MRNA) has touched the lower band of the channel.
The price went outside of the Bollinger Bands (BB) and closed back inside.
This could be the moment of a reversal...
M1RN34 trade ideas
Moderna - Correction Almost Done!Hello TradingView Family / Fellow Traders. This is Richard, also known as theSignalyst.
📈 MRNA has been overall bullish , trading above the trendline marked in blue.
Currently, MRNA is undergoing a correction phase in the shape of a falling channel.
Moreover, it is retesting massive support zone in green.
🏹 Thus, the highlighted blue circle is a strong area to look for trend-following buy setups as it is the intersection of the green support and lower blue/red trendlines acting as non-horizontal support.
📚 As per my trading style:
As #MRNA approaches the blue circle zone, I will be looking for bullish reversal setups (like a double bottom pattern, trendline break , and so on...)
📚 Always follow your trading plan regarding entry, risk management, and trade management.
Good luck!
All Strategies Are Good; If Managed Properly!
~Rich
Pharmacies are very over bookedThis has nothing to do with politics, shut downs or any misinformation on COV1D.
I went to fill my Adderall prescription at my local pharmacy and it took 30 minutes. I have never seen a bigger line in Safeway.
I proceeded to ask the pharmacist, why are you so busy and when did it start? She responded with "vaccines are why, there is only MRNA to choose from".
This is purely based on seasonal demand and we should be hearing more about this in the news within the next couple of months.
Thecnical reasons:
RSI and MACD are ticking up on the larger time frames. Very over sold.
MRNA Taking Profit, Watching for a add LONG after a pullback.MRNA has been on fire since the earnings beat 4 weeks ago and has added 60% to its market cap
in the past three months. It compares well with NVAX which as a prior penny stock has more
volatility and upside potential. In general vaccine stocks are performing well as COVID RSV
and influenza vaccines are active in research are Viral Hepatitis vaccine enhancements and
the drive for an HIV vaccine.
MRNA is strong and perhaps becoming overbought. The mass index indicator has topped and
maybe falling to the trigger line. I will take a one- third partial off my position here
and wait for a pullback with reversal to add back into the position at a lower price.
The tandem of MRNA and NVAX has been very profitable for me. Careful in trade management
will help me keep it that way.
$MRNA. Ready for a boost? Today the markets took a toll but caught a bounce by the end of market close. A few sectors did hold up well structure wise. Those sectors were AMEX:XLV and $XLC. With this in mind, a flow order came in today for $MRNA. NASDAQ:MRNA trades within the AMEX:XLV sector (Healthcare) so automatically this caught my eye. This order is a $155 call expiring 6/7. With the healthcare holding up and this order is bullish on mrna it seems like we will long this ticker into 6/7.
Price Action & Zones:
We are in a trending parallel right now (buyers getting in control). Within the parallel it seems we took out the buyers and the sellers and then price came back into the range. Expected range is $160.84 for the upside and $134.80 for the downside, liquidity will lay at these levels. Watering hole from $152.97 - $154.01.
Entry/Add/Target/Exit:
Entry is on 50-60% discount or a gap up and hold for a while, maybe a chop and a C leg to follow. The add time is market close (if we enter market open). Target is when we are up 50-70% of our contracts value (hold a runner). Exit is if we lose upwards momentum and tank past 60% discount.
MODERNA (MRNA)Moderna stock is the vaccine stock with the largest market cap. Currently, there are issues regarding the outbreak of COVID-19 and other diseases, which is part of the story. However, the most important factor is that vaccine stocks are seeing buying interest across all sectors. This made me interested in the leader that has a clear volume profile in the accumulation zone and is one of the largest companies by market capitalization.
MRNA A Promising Investment Opportunity Moderna, Inc., a pioneering biotechnology firm, has been at the forefront of mRNA technology, revolutionizing the way we approach vaccines and therapeutics. As of now, Moderna's stock exhibits strong momentum, capturing the attention of investors and analysts alike.
### Investment Thesis
**Strong Momentum:** Moderna's stock has shown impressive performance, underpinned by robust financials and the successful rollout of its COVID-19 vaccine. The company's ability to rapidly develop and commercialize its mRNA vaccine has not only generated significant revenue but has also demonstrated the potential of its mRNA platform for other therapies.
**Target Prices:** Analyzing the weekly trading frame, Moderna shows potential to reach target prices of $138 and $162. These targets are based on technical analysis, considering the stock’s current trajectory and market conditions. The momentum is strong, and if it continues, reaching these levels could be plausible in the forthcoming period.
**Stop Loss Consideration:** To manage risk, a stop loss at $94 is advisable. This level is strategically placed to protect investments from unexpected market volatilities while allowing room for the stock to fluctuate and realize its potential.
### Market Position and Future Prospects
Moderna’s success with its COVID-19 vaccine has provided a substantial financial cushion and has accelerated its research and development pipeline. The company is actively expanding its portfolio, including vaccines for influenza, HIV, and other diseases, which could be game-changers in the pharmaceutical industry.
### Conclusion
With a strong market position, promising pipeline, and ongoing positive momentum, Moderna (MRNA) represents a compelling investment opportunity. Targeting $138 and $162 with a strategic stop loss at $94 on the weekly frame, investors could potentially capitalize on Moderna’s innovative approach to medicine and its growing impact on global health.
MRNA Moderna Options Ahead of EarningsIf you haven`t sold MRNA at all time high:
Then analyzing the options chain and the chart patterns of MRNA Moderna prior to the earnings report this week,
I would consider purchasing the 115usd strike price Calls with
an expiration date of 2024-7-19,
for a premium of approximately $8.00.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Moderna Breaks Out 12.68% For The First Time In A YearModerna ( NASDAQ:MRNA ) stock broke out for the first time in a year after beating Wall Street's first-quarter expectations as its second potential approval looms. The company hopes to win Food and Drug Administration approval for its RSV vaccine, which causes cold-like symptoms in most people but can be serious or deadly in babies and older adults. The FDA is due to make its decision on Moderna's shot in less than two weeks. Moderna ( NASDAQ:MRNA ) hopes to launch its vaccine for older adults this fall. If approved, this would be Moderna's second commercial product behind its Covid vaccine.
Moderna's Covid vaccine sales plummeted nearly 91% to $167 million during the first quarter, but handily beat analysts' forecast for $93 million. The European Union plans to buy up to 36 million doses of its Covid vaccine each year for at least four years. The company expects "higher vaccination uptake" in the U.S. if its updated Covid vaccine is available in time with the seasonal flu shot.
From a financial standpoint, Moderna ( NASDAQ:MRNA ) is retaining its outlook for the year. The company expects to notch $4 billion in sales of its respiratory vaccines. That will be weighted to the back half of the year with less than $300 million in sales projected for the first half of 2024. Moderna ( NASDAQ:MRNA ) stock analysts project $4.19 billion in full-year revenue, including $4.06 billion in sales from the company's products.
The RSV vaccine could be a big moneymaker for Moderna ( NASDAQ:MRNA ). Pfizer and GSK launched their RSV shots for older adults last year, with Abrysvo and Arexvy generating $145 million and $228 million in sales respectively. Moderna stock analysts already expect some sales of Moderna's product — $10 million in the June quarter, according to FactSet.
Moderna is ( NASDAQ:MRNA ) also planning to work with U.S. regulators on the timing of its next Covid vaccine. Officials will choose the next variant to target in booster shots on May 16, then it will be off to the races, so to speak, to run testing for Moderna's updated shot. Moderna's goal is to launch the Covid booster shot in timing with the fall flu vaccine campaign.
Moderna's Vaccine Spark Hope in Head and Neck Cancer TreatmentIn a significant breakthrough for cancer treatment, Moderna's ( NASDAQ:MRNA ) individualized cancer vaccine, developed in collaboration with Merck, has shown remarkable promise in an early-stage trial targeting head and neck cancer. The encouraging results have ignited a surge in Moderna's stock price and injected fresh optimism into the field of oncology research.
The vaccine, mRNA-4157, aims to train the immune system to identify and combat specific mutations present in cancer cells, representing a pioneering approach in personalized cancer therapy. Following its success in treating melanoma, the vaccine has now demonstrated positive responses in patients with head and neck squamous cell carcinoma, a challenging form of cancer.
Data presented at the American Association for Cancer Research Annual Meeting showcased the vaccine's efficacy when administered in combination with Merck's Keytruda. The study, involving 22 patients, revealed promising clinical responses, including instances of complete remission. Notably, the combination therapy not only triggered robust immune responses but also exhibited favorable safety profiles, marking a significant milestone in cancer immunotherapy.
Jefferies analyst Michael Yee lauded the results, highlighting the potential of Moderna's therapy platform to transcend melanoma and extend its benefits to other cancer types. The data underscore the transformative potential of mRNA-based vaccines in revolutionizing cancer treatment paradigms and offering new hope to patients grappling with advanced malignancies.
The positive outcome has bolstered investor confidence in Moderna ( NASDAQ:MRNA ), propelling its shares to a three-month high. This uptrend reflects renewed enthusiasm for the biotech firm's diverse pipeline, which includes groundbreaking vaccines targeting respiratory syncytial virus and other infectious diseases, alongside innovative cancer therapies.
Looking ahead, Moderna's collaboration with Merck signals a concerted effort to advance the development of cancer immunotherapies. The initiation of a Phase 3 trial targeting lung cancer underscores the commitment to translating promising preclinical data into clinically meaningful outcomes, to deliver transformative therapies to patients in need.
As Moderna ( NASDAQ:MRNA ) continues to pioneer the frontier of mRNA-based therapeutics, the recent success of its cancer vaccine heralds a new era in precision medicine. With further advancements and clinical validations, this innovative approach holds the potential to reshape the landscape of cancer treatment and offer renewed hope for patients battling this devastating disease.
This is why vax stocks are going to explode from here ! I have looked at the charts of Moderna and explained why I'm so bullish this stock as well as the general sector. We should expect a catalyst show up in the news in the very near future which should cause a big spike in this sector and that cannot be good for the overall market.
Given a breakout of this area we should see a great climbHere's a small interesting history:
In the late 19th century, stock trading took place through an archaic system of handwritten ledger entries and paper shares that had to be physically transported between offices. This cumbersome process led to frequent errors and delays. In 1887, a group of Wall Street clerks devised a more efficient method by setting up networks of pneumatic tubes to rapidly shuttle documents between brokerage houses and the exchange floor. This "mail tube" system, patented in 1892, could propel cylindrical cartridges containing stock certificates and instructions through a maze of underground pipes at speeds of up to 35 mph - a revolutionary breakthrough for finance at the time. The pneumatic tube network grew to span 27 miles of subterranean tubing and remained an integral part of Wall Street trading until the 1960s when it was replaced by digital tickertapes and information networks.
